Tabata Mika Michelle, Kwong Bernice
Dermatology, Stanford University School of Medicine, Stanford, California, USA.
Dermatology, Stanford Medicine, Stanford, California, USA.
BMJ Case Rep. 2019 Jul 21;12(7):e230023. doi: 10.1136/bcr-2019-230023.
Recognition of new cutaneous side effects of combination chemotherapy can help prevent unnecessary cessation or reduction of cancer therapy. Periorbital rash has not been found with docetaxel alone, but here, we report it as a result of combination chemotherapy. A series of three patients who received docetaxel in combination with other chemotherapies developed clinically near-identical, distinctive periorbital rashes. Rashes resolved by resolving underlying docetaxel-induced epiphora in conjunction with ophthalmological consultation, topical skin-directed care, and in some cases, chemotherapy dose reduction. It is important for dermatologists and oncologists to recognise the increased severity of cutaneous reactions when docetaxel is used in combination chemotherapy.
认识联合化疗新的皮肤副作用有助于预防不必要地停止或减少癌症治疗。单独使用多西他赛时未发现眶周皮疹，但在此我们报告联合化疗导致了眶周皮疹。三名接受多西他赛与其他化疗联合治疗的患者出现了临床上几乎相同的、独特的眶周皮疹。通过解决潜在的多西他赛引起的溢泪问题，结合眼科会诊、局部皮肤护理，在某些情况下减少化疗剂量，皮疹得以消退。皮肤科医生和肿瘤学家认识到多西他赛用于联合化疗时皮肤反应严重程度增加很重要。
